These proteins, called MDM2 and MDMX, become overactive in cancer ... and researchers are exploring several promising options. Advances in gene-editing technologies like CRISPR are opening doors ...

The orally-available MDM2-p53 agonist is designed to restore the function of p53, the most frequently mutated gene in cancer, which has so far resisted drug development efforts. The p53 gene ...

A team of CiRA researchers has uncovered the crucial role of EIF3D—a protein translational regulator—in primed pluripotency.

1). BI 907828 binds directly to MDM2 and blocks its interaction with p53, leading to stabilization of p53, TP53 target gene induction, cell-cycle arrest and apoptosis in tumour cells with wild ...

Western blot assays were performed to identify the presence of p53, phospho-p53, and murine double minute 2 (MDM2) isoforms in plasma samples. Densitometric analysis was used to determine the ...